What is Linkage Therapeutics?
Linkage Therapeutics is a biotechnology company developing intracellular intrabody therapeutics to treat neurodegenerative diseases. The company focuses on precision protein clearance, using engineered antibodies that work inside cells to selectively remove toxic, disease-causing proteins.
What diseases does Linkage Therapeutics target?
Linkage Therapeutics is developing therapeutics for major neurodegenerative diseases, including:
- Alzheimer’s disease
- Parkinson’s disease
- Huntington’s disease
The company’s pipeline is anchored in validated disease biology and addresses conditions driven by toxic protein accumulation.
What is the PTAP™ platform?
The PTAP™ (Programmable Target Antigen Proteolysis) platform is Linkage Therapeutics’ proprietary technology for tunable, ubiquitin-independent degradation of intracellular proteins. PTAP enables selective and controllable clearance of pathogenic proteins while preserving normal cellular function.
What are intrabodies?
Intrabodies are engineered antibody fragments designed to function inside cells, where many disease-causing proteins accumulate. Unlike conventional antibodies, intrabodies can bind intracellular targets and modulate protein behavior directly at the source of pathology.
How is Linkage Therapeutics’ approach different from other protein degradation technologies?
Linkage Therapeutics’ intrabody-based approach differs from other protein degradation strategies by:
- Operating inside cells, not just extracellularly
- Enabling high target specificity
- Allowing tunable protein clearance, rather than complete elimination
- Using ubiquitin-independent proteasomal degradation for long-term control
This precision reduces off-target effects and supports sustained therapeutic benefit.
What stage are Linkage Therapeutics’ programs?
Linkage Therapeutics’ lead programs are in preclinical development, with externally validated data and a clear path toward IND-enabling studies. The company is advancing its lead neurodegeneration programs toward clinical readiness.
What is the lead program at Linkage Therapeutics?
The company’s lead program targets mutant huntingtin (mHTT) in Huntington’s disease using a bifunctional intrabody designed to selectively clear toxic protein aggregates while preserving normal huntingtin function.
Does Linkage Therapeutics have data supporting its platform?
Yes. Linkage Therapeutics has generated robust preclinical data across multiple disease models, including in vivo studies and human brain organoid systems, demonstrating reduction of toxic protein aggregation, improved cellular health, and functional benefit.
Is the PTAP platform validated across multiple targets?
Yes. The PTAP platform has been validated across multiple neurodegenerative targets, including tau, α-synuclein, and mutant huntingtin, supporting its use as a broad, modular therapeutic platform.
Who leads Linkage Therapeutics?
Linkage Therapeutics is led by experienced scientists with internationally recognized expertise in neurodegeneration, intrabody engineering, gene therapy, and translational neuroscience. The leadership team has a strong track record of moving innovative biological technologies toward the clinic.
Does Linkage Therapeutics partner with other companies?
Yes. Linkage Therapeutics is partner-focused and collaborates with biotechnology companies, pharmaceutical organizations, academic institutions, and strategic partners to advance its programs and platform.
How is Linkage Therapeutics funded?
Linkage Therapeutics is pursuing a platform-plus-lead-indication strategy and is raising capital to support IND-enabling studies, manufacturing, and clinical development of its neurodegeneration pipeline.
What is the long-term vision of Linkage Therapeutics?
The long-term vision of Linkage Therapeutics is to build the first precision intrabody therapeutics company dedicated to transforming the treatment of neurodegenerative diseases by clearing toxic proteins at their source.
How can I contact Linkage Therapeutics?
You can contact Linkage Therapeutics through the Contact page on the website to inquire about partnerships, investment opportunities, or scientific collaboration.